13F Holdings
中文EN

BFRI Biofrontera Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1858685 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.8%
TTM net income YoY61.6%
TTM EPS YoY76.4%
Revenue 3-yr CAGR16.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-14.2%
Net margin-13.8%
FCF margin-17.2%
EBITDA margin-14.0%

Returns

ROE-988.4%
ROA-28.8%
ROIC (approx.)—
Asset turnover2.09x

Leverage & solvency

Liabilities / assets75.2%
Debt / equity0.00x
Current ratio1.18x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.25x
Accruals ratio7.1%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$41.70M$37.32M$34.07M$28.67M$24.10M
R&D expense$3.72M$2.09M$77,000——
SG&A expense$37.75M$33.79M$18.49M$35.14M$36.51M
Operating income-$11.35M-$17.21M-$22.68M-$18.58M-$25.20M
Interest expense——$220,000$12,000$344,000
Pretax income-$10.51M-$17.74M-$20.12M-$608,000-$37.66M
Income tax$25,000$22,000$14,000$32,000$56,000
Net income-$10.54M-$17.76M-$20.13M-$640,000-$37.71M
EBITDA-$11.21M-$16.79M-$22.08M-$18.48M-$25.08M
EPS (basic)-1.04-3.22-13.02-0.61-4.28
EPS (diluted)-1.04-3.22-13.02-0.61-4.28
Weighted avg. shares (diluted)10.17M5.52M1.55M1.06M8.81B
Banking
Net interest income——-$468,000-$195,000-$344,000
Balance sheet
Cash & equivalents$6.39M$5.91M$1.34M$17.21M$24.55M
Receivables$7.29M————
Inventory$1.43M$6.65M$10.91M$7.17M$4.46M
Current assets$18.08M$20.70M$23.07M$43.14M$46.42M
PP&E, net$2.16M$80,000$134,000$204,000$267,000
Intangibles$2.65M$35,000$2.63M$3.03M$3.45M
Total assets$28.56M$22.10M$27.93M$50.88M$53.22M
Current liabilities$11.89M$12.02M$18.09M$20.89M$13.84M
Short-term debt——$3.90M——
Total liabilities$18.08M$17.67M$23.14M$27.01M$41.88M
Shareholders' equity$10.48M$4.43M$4.79M$23.88M$11.34M
Shares outstanding11.65M8.87M1.52M1.33M17.10M
Cash flow statement
Operating cash flow-$13.36M-$10.27M-$24.89M-$16.20M-$26.71M
Capital expenditure$2,000$10,000$5,000$38,000—
Free cash flow-$13.36M-$10.28M-$24.90M-$16.24M—
Investing cash flow$3.00M-$3,000$619,000-$5.16M-$11,000
Financing cash flow$10.85M$14.84M$8.41M$14.02M$43.19M
Depreciation & amortization$138,000$421,000$600,000$101,000$122,000
Stock-based compensation$951,000$1.02M$1.04M$1.85M$129,000

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.